|OliX Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA|
|Date : 2023-06-02 View : 621|
OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital·BioHealth Business Forum
-OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Korea Health Industry Development Institute.
-The Company signed an MOU with DynamiCure Biotechnology to develop an ADC immunotherapy using RNA technology.
SUWON, South Korea, May 10, 2023 -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company signed a memorandum of understanding (MOU) with DynamiCure Biotechnology for developing an RNA-based antibody-drug conjugate (ADC) therapeutics at the Korea-US Digital·BioHealth Business Forum recently held in Boston, Massachusetts.
The Ministry of Health and Welfare of Korea and Korea Health Industry Development Institute hosted Korea-US Digital·BioHealth Business F as one of the five Korean companies to sign a collaboration agreement with a U.S. company. At the event, OliX inked an MOU with DynamiCure to agree on innovative technological collaboration for developing RNA-ADC therapeutics.
DynamiCure Biotechnology specializes in developing oncology drugs and autoimmune therapies with antibody technology. The company owns an anticancer pipeline, which is currently in the clinical stage, with a mechanism of targeting a receptor that affects the abnormal development of tumor vasculature.
Meanwhile, Dong Ki Lee, Ph.D., Founder of the business delegation members and accompanied South Korean President Yoon Suk Yeol on his state visit to the U.S. While staying in the U.S., Dr. Leeparticipated in official occasions including the Korea-U.S. Advanced Industry Forum hosted by the U.S. Chamber of Commerce, and the official welcoming ceremony held by the U.S. government at the White House.
|Prev||OliX Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide|
|Next||OliX Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment|